|
HINT3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.92200000049515E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.14649999999983E-05 |
| Normal-vs-Stage2 |
1.455250E-03 |
| Normal-vs-Stage3 |
1.6180999999893E-06 |
| Normal-vs-Stage4 |
7.96229999711073E-08 |
| Stage1-vs-Stage2 |
8.905400E-01 |
| Stage1-vs-Stage3 |
3.834400E-01 |
| Stage1-vs-Stage4 |
3.076400E-02 |
| Stage2-vs-Stage3 |
4.670400E-01 |
| Stage2-vs-Stage4 |
1.021180E-01 |
| Stage3-vs-Stage4 |
2.333800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.90589999968938E-07 |
| Normal-vs-AfricanAmerican |
9.109900E-02 |
| Normal-vs-Asian |
1.611940E-04 |
| Caucasian-vs-AfricanAmerican |
1.360620E-01 |
| Caucasian-vs-Asian |
9.054400E-01 |
| AfricanAmerican-vs-Asian |
1.843160E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.27659998922547E-09 |
| Normal-vs-Female |
3.82800000000572E-05 |
| Male-vs-Female |
1.926070E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.971700E-04 |
| Normal-vs-Age(41-60Yrs) |
7.64609999759358E-08 |
| Normal-vs-Age(61-80Yrs) |
2.94389999999645E-06 |
| Normal-vs-Age(81-100Yrs) |
2.081800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.683240E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.923200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.347600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.481800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.287200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.164800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.348000E-01 |
| Classical-VS-Follicular |
4.200400E-01 |
| Classical-VS-Other |
8.076200E-02 |
| Classical-VS-Normal |
2.14169999999125E-05 |
| Tall-VS-Follicular |
9.409600E-01 |
| Tall-VS-Other |
1.009650E-01 |
| Tall-VS-Normal |
2.240700E-04 |
| Follicular-VS-Other |
2.109000E-01 |
| Follicular-VS-Normal |
1.351050E-04 |
| Other-VS-Normal |
6.596900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.11700000038751E-07 |
| Normal-vs-N1 |
2.41960000035846E-07 |
| N0-vs-N1 |
1.140450E-01 |
|
|
